Citations

Clear

16281 citation(s) found for "Yu, David".

High-grade B-cell lymphoma, not otherwise specified: CNS involvement and outcomes in a multi-institutional series
Zayac, Adam , Bock, Allison M. , Nowakowski, Grzegorz S. , Ayers, Emily C. , Girton, Mark , Hu, Marie , Beckman, Amy , Li, Shaoying , Chang, Julie E , Sandoval‐Sus, Jose , Ansari‐Lari, M. Ali, Kothari, Shalin , Kress, Anna, Xu, Mina L. , Torka, Pallawi , Smith, Stephen D. , Naresh, Kikkeri N. , Karimi, Yasmin , Evens, Andrew M. , Naik, Seema , Kamdar, Manali , Haverkos, Bradley M. , Rubinstein, P , Chaudhry, Amina, Epperla, Narendranath , Zayac, Adam S , Bock, Allison M , Ayers, Emily C , Girton, Mark , Hu, Marie , Li, Shaoying , Medeiros, L Jeffrey , Chang, Julie E , Torka, Pallawi , Smith, Stephen D , Karimi, Yasmin H , Bond, David A , Naik, Seema G , Haverkos, Bradley M , Karmali, Reem , Farooq, Umar , Vose, Julie , Rubinstein, Paul G , Olszewski, Adam J , Evens, Andrew M , Naresh, Kikkeri N , Kamdar, Manali , Epperla, Narendranath , Landsburg, Daniel J. , Medeiros, L. Jeffrey , Kurt, Habibe , Sundaram, Suchitra , Bond, David A. , Karmali, Reem , Vose, Julie M. , Chaudhry, Amina, Olszewski, Adam J.

Mayo Clinic

Blood Advances | August 27, 2024 | Volume: 8 | Issue: 20 | Pages: 5355-5364

10.1182/bloodadvances.2024013791 | PMID 39189932 Get It

Abstract Little is known about the central nervous system (CNS) risk in high-grade B-cell lymphoma, not otherwise specified (HGBL NOS). Hence, we sought to describe the rates of baseline CNS involvement, risk of CNS recurrence after primary therapy, and management strategies in HGBL NOS. In this multicenter retrospective study, we included 160 adults with newly diagnosed HGBL NOS treated between 2016 and 2021 at 20 US institutions. Eleven patients (7%) had baseline CNS involvement at diagnosis (leptomeningeal = 6, parenchymal = 4, and both = 1). Baseline CNS involvement was significantly associated only with MYC rearrangement (OR = 3.5) and testicular (in men) or female pelvic (in women) involvement (OR = 8.1). There was no significant difference in survival outcomes between patients with HGBL NOS with (median PFS = 4 years) or without (median PFS = 2.4 years) baseline CNS involvement (P = 0.45). The cumulative incidence of CNS recurrence at 3 years was 11%. Patients with baseline CNS involvement were at the highest risk (48.5% vs 8% for those without baseline CNS involvement) and were excluded from the risk factors analysis for CNS recurrence. The risk for CNS recurrence was significantly associated with blood or bone marrow involvement, CD5 expression, non–germinal center B-cell subtype, and “dual-expresser lymphoma” phenotype, however, high CNS IPI was not. The prognosis of relapsed HGBL NOS was poor, regardless of whether recurrence was systemic or limited to the CNS, and with currently available salvage strategies, including autologous transplantation and chimeric antigen receptor T-cell modalities, almost all patients with CNS recurrence ultimately succumbed to their disease.
RNA Shielding of p65 Is Required to Potentiate Oncogenic Inflammation in TET2 -Mutated Clonal Hematopoiesis
Ben-Crentsil, Nana Adjoa , Ismail, Wazim Mohammed , Newman, Hannah , Quintana, Ariel , Binder, Moritz , Kruer, Traci , Neupane, Surendra , Ferrall‐Fairbanks, Meghan C. , Fernandez, Jenna , Finke, Christy M. , Ibrahim, Mohammed L. , McGraw, Kathy L. , Wysota, Michael , Aldrich, Amy L. , Letson, Christopher T. , Traina, Joshua , McLemore, Amy F. , Droin, Nathalie , Sallman, David A. , Beg, Amer A. , Ma, Li , Gaspar‐Maia, Alexandre , Patnaik, Mrinal M. , Padron, Eric , Mohammed Ismail, Wazim , Balasis, Maria , Newman, Hannah , Quintana, Ariel , Binder, Moritz , Kruer, Traci , Neupane, Surendra , Ferrall-Fairbanks, Meghan C , Fernandez, Jenna , Lasho, Terra L , Finke, Christy M , Ibrahim, Mohammed L , McGraw, Kathy L , Wysota, Michael , Aldrich, Amy L , Ryder, Christopher B , Letson, Christopher T , Traina, Joshua , McLemore, Amy F , Droin, Nathalie , Shastri, Aditi , Yun, Seongseok , Solary, Eric , Sallman, David A , Beg, Amer A , Ma, Li , Gaspar-Maia, Alexandre , Patnaik, Mrinal , Padron, Eric , Balasis, Maria E. , Lasho, Terra L. , Yun, Seongseok , Solary, Éric

Mayo Clinic

Cancer Discovery | August 27, 2024 | Volume: 14 | Issue: 12 | Pages: 2509-2531

10.1158/2159-8290.cd-24-0093 | PMID 39189614 Get It

Abstract TET2 mutations (mTET2) are common genetic events in myeloid malignancies and clonal hematopoiesis. These mutations arise in the founding clone and are implicated in many clinical sequelae associated with oncogenic feedforward inflammatory circuits. However, the direct downstream effector of mTET2 responsible for the potentiation of these inflammatory circuits is unknown. To address this, we performed scRNA-seq and scATAC-seq in patients with COVID-19 with and without TET2-mutated clonal hematopoiesis reasoning that inflammation from COVID-19 may highlight critical downstream transcriptional targets of mTET2. Using this approach, we identified metastasis-associated lung adenoma transcript 1 (MALAT1), a therapeutically tractable lncRNA, as a central downstream effector of mTET2 that is both necessary and sufficient to induce the oncogenic proinflammatory features of mTET2 in vivo. We also elucidate the mechanism by which mTET2 upregulate MALAT1 and describe an interaction between MALAT1 and p65, which leads to RNA “shielding” from protein phosphatase 2A dephosphorylation, thus preventing resolution of inflammatory signaling. Significance: This work identifies MALAT1 as a requisite downstream effector of oncogenic feedforward inflammatory circuits necessary for the development of TET2-mutated CH and fulminant myeloid malignancy. We elucidate a novel mechanism by which MALAT1 “shields” p65 from dephosphorylation to potentiate this circuit and nominate MALAT1 inhibition as a future therapeutic strategy.
Repetitive Head Impacts and Perivascular Space Volume in Former American Football Players
Jung, Leonard , Wiegand, Tim L. T. , Tuz‐Zahra, Fatima , Iliff, Jeffrey J. , Piantino, Juan , Arciniega, Hector , Kim, Cara L., Pankatz, Lara, Lin, Alexander , Alosco, Michael L. , Daneshvar, Daniel H. , Pasternak, Ofer , Coleman, Michael J. , Bernick, Charles , Balcer, Laura J. , Reiman, Eric M. , Shenton, Martha E., Protas, Hillary , Boker, Conni, Kowall, Neil W. , Otis, James , Weller, Jason , Simkin, Irene, Andino, Alondra, Diamond, Courtney , Fagle, Tessa, Haller, Olivia, Hung, Tennyson, Gullotti, Nicole, Mariani, Megan, Mayville, Brian, McLaughlin, Kathleen , Nanna, Mary, Platt, Taylor, Pulukuri, Sury, Rica, Fiona, Sestak, Madison, Annis, Douglas S. , Dixon, Dianne B., Finney, Carolyn, Gallagher, Kerrin, Hartlage, Kaitlin , Martin, Brett, Palmisano, Joseph , Pine, Brittany, Fitzsimmons, Jennifer, Breedlove, Katherine M. , Coello, Eduardo , Liao, Hujiun, Rizzoni, Elizabeth, Schultz, Vivian , Silva, Annelise, Vessey, Brynn, Banks, Sarah J. , Ritter, Aaron, Sabbagh, Marwan N. , Cruz, Raelynn de la, Durant, Jan, Golceker, Moragn, Harmon, Nicolette, Kaylegian, Kaeson, Long, Rachelle, Nance, Christin, Sandoval, Priscilla, Serrano, Andrew, Falk, Bryce W., Duffy, Amy, Howard, Marci, Montague, Michelle , Osgood, Thomas, Babcock, Debra, Kirov, Ivian, Marmar, Charles R. , Hasanaj, Lisene, Serrano, Liliana , Al-Kharafi, Alhassan, George, Allan , Martin, Sammie, Runge, William, Peskind, Elaine R. , Colasurdo, Elizabeth A. , Marcus, Daniel S. , Gurney, Jenny , Johnson, Keith A. , Greenwald, Richard M., Shenton, Martha E. , Daneshvar, Daniel H , Shenton, Martha E , Tripodis, Yorghos , Bouix, Sylvain , Mez, Jesse , Sepehrband, Farshid , Rathi, Yogesh , Adler, Charles H. , Cummings, Jeffrey L. , Stern, Robert A. , Koerte, Inga K , Su, Yi , Chen, Kewei , Boker, Connie, Au, Rhoda , Cantu, Robert C. , Farrer, Lindsay A. , Helm, Robert H. , Mercier, Gustavo , Conneely, Shannon E. , Diamond, Courtney, Pulukuri, Surya Vamsi , McClean, Michael D , Annis, Douglas, Chaisson, Christine E. , Finney, Carolyn, Lü, Jun , Ojo, Emmanuel, Ramachandran, Janani , Bonke, Elena M. , Breedlove, Katherine , Miller, Jason Rafe , II, Robert W. Turner , Marek, Kenneth , Dodick, David W. , Geda, Yonas E. , Wethe, Jennifer V. , Falk, Bryce, Montague, Michelle, Barr, William , Goldberg, Judith D. , Wısnıewskı, Thomas , Lui, Yvonne W. , George, Allan, Riley, Edward P.

Mayo Clinic

JAMA Network Open | August 26, 2024 | Volume: 7 | Issue: 8 | Pages: e2428687

10.1001/jamanetworkopen.2024.28687 | PMID 39186275 Get It

ImportanceExposure to repetitive head impacts (RHI) is associated with increased risk for neurodegeneration. Accumulation of toxic proteins due to impaired brain clearance is suspected to play a role.ObjectiveTo investigate whether perivascular space (PVS) volume is associated with lifetime exposure to RHI in individuals at risk for RHI-associated neurodegeneration.Design, Setting, and ParticipantsThis cross-sectional study was part of the Diagnostics, Imaging, and Genetics Network for the Objective Study and Evaluation of Chronic Traumatic Encephalopathy (DIAGNOSE CTE) Research Project, a 7-year multicenter study consisting of 4 US study sites. Data were collected from September 2016 to February 2020 and analyses were performed between May 2021 and October 2023. After controlling for magnetic resonance image (MRI) and processing quality, former American football players and unexposed asymptomatic control participants were included in analyses.ExposurePrior exposure to RHI while participating in American football was estimated using the 3 cumulative head impact indices (CHII-G, linear acceleration; CHII-R, rotational acceleration; and CHII, number of head impacts).Main Outcomes and MeasuresIndividual PVS volume was calculated in the white matter of structural MRI. Cognitive impairment was based on neuropsychological assessment. Linear regression models were used to assess associations of PVS volume with neuropsychological assessments in former American football players. All analyses were adjusted for confounders associated with PVS volume.ResultsAnalyses included 224 participants (median [IQR] age, 57 [51-65] years), with 170 male former football players (114 former professional athletes, 56 former collegiate athletes) and 54 male unexposed control participants. Former football players had larger PVS volume compared with the unexposed group (mean difference, 0.28 [95% CI, 0.00-0.56]; P = .05). Within the football group, PVS volume was associated with higher CHII-R (β = 2.71 × 10−8 [95% CI, 0.50 × 10−8 to 4.93 × 10−8]; P = .03) and CHII-G (β = 2.24 × 10−6 [95% CI, 0.35 × 10−6 to 4.13 × 10−6]; P = .03). Larger PVS volume was also associated with worse performance on cognitive functioning in former American football players (β = −0.74 [95% CI, −1.35 to −0.13]; P = .04).Conclusions and RelevanceThese findings suggest that impaired perivascular brain clearance, as indicated by larger PVS volume, may contribute to the association observed between RHI exposure and neurodegeneration.
Lymph node staging and treatment in pediatric patients with soft tissue sarcomas: A consensus opinion from the Children’s Oncology Group, European paediatric Soft tissue sarcoma Study Group, and the Cooperative Weichteilsarkom Studiengruppe
Scheltinga, Scheila E. J. Terwisscha van, Keizer, Bart de , McCarville, M. Beth , Casey, Dana L. , Walterhouse, David , Hiemcke‐Jiwa, Laura S. , Franzius, Christiane, Vokuhl, Christian , Birz, Suzi , Rodeberg, David A. , Casey, Dana L , de Keizer, Bart , Schoot, Reineke A , Routh, Jonathan C. , Seitz, Guido , Kao, Simon C. , Shulkin, Barry L. , Ewijk, Roelof van , Allen‐Rhoades, Wendy , Mercolini, Federico , Merks, Johannes H M , Orbach, Daniel , Kapadia, Tejas , Fajardo, Raquel Dávila , Corti, Federica De , Tang, Vivian , Metts, Jonathan L. , Oberoi, Saphna , Dasgupta, Roshni

Mayo Clinic

No container title available | August 23, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.172445880.02878798/v1 Get It

Accurate staging of nodal involvement in pediatric sarcoma patients is important to determine correct systemic and local therapy, with the goal to reduce subsequent recurrences. However, differences in lymph node staging strategies, definitions, and treatment protocols between the Children’s Oncology Group (COG), European Pediatric Soft Tissue Sarcoma Study Group (EpSSG), and the Cooperative Weichteil Sarkom Studiengruppe (CWS), complicate comparisons. In this article we try to establish internationally recognized recommendations for lymph node assessment and treatment of children and adolescents diagnosed with RMS and NRSTS according to the Consensus Conference Standard Operating Procedure methodology.
Comparison of combined intravenous and intra-arterial thrombolysis with intravenous thrombolysis alone in stroke patients undergoing mechanical thrombectomy: a propensity-matched analysis
Elawady, Sameh Samir , Kasem, Rahim Abo , Mulpur, Bhageeradh , Matsukawa, Hidetoshi , Sowlat, Mohammad‐Mahdi , Orscelik, Atakan , Nawabi, Noah, Isidor, Julio , Maier, Ilko , Jabbour, Pascal , Kim, Joon‐Tae , Wolfe, Stacey Q , Rai, Ansaar, Starke, Robert M. , Psychogios, Marios‐Nikos, Yoshimura, Shinichi , Alaraj, Ali , Ezzeldin, Mohamad , Tanweer, Omar , Polifka, Adam , Siddiqui, Fazeel , Crosa, Roberto , Brinjikji, Waleed , Moss, Mark, Dağlıoğlu, Ergün , Williamson, Richard A., Kan, Peter , Chowdhry, Shakeel , Altschul, David , Spiotta, Alejandro M , Abo Kasem, Rahim , Matsukawa, Hidetoshi , Sowlat, Mohammad-Mahdi , Orscelik, Atakan , Maier, Ilko , Jabbour, Pascal , Wolfe, Stacey Quintero , Cuellar-Saenz, Hugo H , Howard, Brian M , Alaraj, Ali , Mascitelli, Justin R , Fragata, Isabel , Osbun, Joshua W , Grandhi, Ramesh , Crosa, Roberto , Matouk, Charles , Brinjikji, Waleed , Navia, Pedro , Kan, Peter , De Leacy, Reade , Altschul, David J , Spiotta, Alejandro M , Levitt, Michael R , Cunningham, Conor M. , Jabbour, Pascal , Rai, Ansaar , Samaniego, Edgar A , Cuellar, Hugo , Alawieh, Ali , Romano, Daniele Giuseppe , Fragata, Isabel , Grandhi, Ramesh , Matouk, Charles , Park, Min S. , Williamson, Richard, Navía, Pedro , Leacy, Reade De , Levitt, Michael R. , Goyal, Nitin

Mayo Clinic

Journal of NeuroInterventional Surgery | August 23, 2024 | Volume: 17 | Issue: e2 | Pages: e261-e268

10.1136/jnis-2024-021975 | PMID 39179373 Get It

Background A combination of intravenous (IVT) or intra-arterial (IAT) thrombolysis with mechanical thrombectomy (MT) for acute ischemic stroke due to large vessel occlusion (AIS-LVO) has been investigated. However, there is limited data on patients who receive both IVT and IAT compared with IVT alone before MT. Methods STAR data from 2013 to 2023 was utilized. We performed propensity score matching between the two groups. The primary outcomes were symptomatic intracranial hemorrhage (sICH) and 90-day modified Rankin Scale (mRS) score 0–2. Secondary outcomes included successful recanalization (modified treatment in cerebral infarction (mTICI) ≥2B, ≥2C), early neurological improvement, any intracranial hemorrhage (ICH), and 90-day mortality. Results A total of 2454 AIS-LVO patients were included. Propensity matching yielded 190 well-matched patients in each group. No significant differences were observed between the groups in either ICH or sICH (odds ratio (OR): 0.80, 95% confidence interval (CI) 0.51–1.24, P=0.37; OR: 0.60, 95% CI 0.29 to 1.24, P=0.21, respectively). Rates of successful recanalization and early neurological improvement (ENI) were significantly lower in MT+IVT + IAT. mRS 0–1 and mortality were not significantly different between the two groups. However, the MT+IVT + IAT group demonstrated superior rates of good functional outcomes (90-day mRS 0–1) compared with patients in the MT+IVT group who had mTICI ≤2B, (OR: 2.18, 95% CI 1.05 to 3.99, P=0.04). Conclusion The combined use of IAT and IVT thrombolysis in AIS-LVO patients undergoing MT is safe. Although the MT+IVT+ IAT group demonstrated lower rates of recanalization and early neurological improvement, long-term functional outcomes were favorable in this group suggesting a potential delayed benefit of IAT.
Artificial Intelligence Models Are Limited in Predicting Clinical Outcomes Following Hip Arthroscopy
Mehta, Apoorva , El-Najjar, Dany , Howell, Harrison J. , Gupta, Puneet , Arciero, Emily , Marigi, Erick M. , Parisien, Robert L. , Howell, Harrison , Trofa, David P , Marigi, Erick , El-Najjar, Dany B , Gupta, Puneet

Mayo Clinic

JBJS Reviews | August 23, 2024 | Volume: 12 | Issue: 8 | Pages: No page available

10.2106/jbjs.rvw.24.00087 | PMID 39172870 Get It

Background: Hip arthroscopy has seen a significant surge in utilization, but complications remain, and optimal functional outcomes are not guaranteed. Artificial intelligence (AI) has emerged as an effective supportive decision-making tool for surgeons. The purpose of this systematic review was to characterize the outcomes, performance, and validity (generalizability) of AI-based prediction models for hip arthroscopy in current literature. Methods: Two reviewers independently completed structured searches using PubMed/MEDLINE and Embase databases on August 10, 2022. The search query used the terms as follows: (artificial intelligence OR machine learning OR deep learning) AND (hip arthroscopy). Studies that investigated AI-based risk prediction models in hip arthroscopy were included. The primary outcomes of interest were the variable(s) predicted by the models, best model performance achieved (primarily based on area under the curve, but also accuracy, etc), and whether the model(s) had been externally validated (generalizable). Results: Seventy-seven studies were identified from the primary search. Thirteen studies were included in the final analysis. Six studies (n = 6,568) applied AI for predicting the achievement of minimal clinically important difference for various patient-reported outcome measures such as the visual analog scale and the International Hip Outcome Tool 12-Item Questionnaire, with area under a receiver-operating characteristic curve (AUC) values ranging from 0.572 to 0.94. Three studies used AI for predicting repeat hip surgery with AUC values between 0.67 and 0.848. Four studies focused on predicting other risks, such as prolonged postoperative opioid use, with AUC values ranging from 0.71 to 0.76. None of the 13 studies assessed the generalizability of their models through external validation. Conclusion: AI is being investigated for predicting clinical outcomes after hip arthroscopy. However, the performance of AI models varies widely, with AUC values ranging from 0.572 to 0.94. Critically, none of the models have undergone external validation, limiting their clinical applicability. Further research is needed to improve model performance and ensure generalizability before these tools can be reliably integrated into patient care. Level of Evidence: Level IV . See Instructions for Authors for a complete description of levels of evidence.
Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysis
Cremer, Paul , Brucato, Antonio , Lin, David , Kwon, Deborah , Jellis, Christine , Clair, JoAnn , Curtis, Allison , Wang, Sheldon, Paolini, John F. , Luis, Sushil A , Jellis, Christine L , Brucato, Antonio , Cremer, Paul C , Insalaco, Antonella , Luis, Sushil Allen , Klein, Allan L. , Imazio, Massimo

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | August 22, 2024 | Volume: 26 | Issue: 1 | Pages: 72-79

10.1093/ehjci/jeae200 | PMID 39172552 Get It

Abstract Aims In the Phase 3 trial, RHAPSODY, rilonacept effectively resolved active pericarditis recurrences, and long-term treatment led to sustained pericarditis recurrence risk reduction. Prior analysis suggested association between higher late gadolinium enhancement (LGE) at baseline and more rapid recurrence upon rilonacept suspension after 12 weeks of treatment. This subgroup analysis assessed the utility of longitudinal serial cardiac magnetic resonance (CMR) imaging for tracking clinical improvement and predicting post-treatment cessation outcomes to help guide clinical decision-making. Methods and results At an 18-month decision milestone (18MDM) in the RHAPSODY long-term extension, investigators decided if patients would continue rilonacept, suspend rilonacept for off-treatment observation, or discontinue the study. Pericardial thickness, pericardial oedema (T2-short tau inversion recovery, T2-STIR), and LGE were determined at baseline and 18MDM by an imaging core lab blinded to clinical data, and pericarditis recurrence was investigator-assessed. CMR results in patients with data at both baseline and 18MDM (n = 13) showed that pericardial thickness, T2-STIR, and LGE were reduced during rilonacept treatment. Among patients with CMR data who suspended rilonacept at the 18MDM (n = 7), five (71%) had a pericarditis recurrence within 1–4 months of rilonacept suspension, despite all having had none/trace LGE (n = 7) and negative T2-STIR (n = 7) at the 18MDM and two having received prophylactic colchicine. Conclusion Continued clinical improvement during prolonged rilonacept treatment corresponded with improvement on CMR, including reduced pericardial thickness, resolution of pericardial oedema, and resolution of LGE. However, none/trace LGE at 18MDM while on treatment did not predict absence of pericarditis recurrence upon subsequent rilonacept suspension in this size-limited subgroup.
Isolation and characterization of bone mesenchymal cell small extracellular vesicles using a novel mouse model
Monroe, David G. , Javeed, Naureen , Ruan, Ming, McCabe, Chantal E. , Piatkowski, Bryan T, Roy, Abhishek, Bobbili, Madhusudhan Reddy , Grillari, Johannes , Khosla, Sundeep , Piatkowski, Bryan , Rowsey, Jennifer L. , Khosla, Sundeep , Monroe, David G , Javeed, Naureen , Piatkowski, Bryan T , Roy, Abhishek

Mayo Clinic

Journal of Bone and Mineral Research | August 22, 2024 | Volume: 39 | Issue: 11 | Pages: 1633-1643

10.1093/jbmr/zjae135 | PMID 39173022 Get It

Abstract Extracellular vesicles (EVs) are key mediators of cell–cell communication and are involved in transferring specific biomolecular cargo to recipient cells to regulate their physiological functions. A major challenge in the understanding of EV function in vivo is the difficulty ascertaining the origin of the EV particles. The recent development of the “Snorkel-tag,” which includes EV-membrane-targeted CD81 fused to a series of extra-vesicular protein tags, can be used to mark EVs originating from a specific source for subsequent isolation and characterization. We developed an in vivo mouse model, termed “CAGS-Snorkel,” which expresses the Snorkel-tag under the control of the Cre-lox system, and crossed this mouse with either Prx1-Cre (mesenchymal progenitors) or Ocn-Cre (osteoblasts/osteocytes) and isolated Snorkel-tagged EVs from the mouse bone marrow plasma using a magnetic bead affinity column. miRNA-sequencing was performed on the isolated EVs, and although similar profiles were observed, a few key miRNAs involved in bone metabolism (miR-106b-5p, miRs-19b-3p, and miRs-219a-5p) were enriched in the Ocn-derived relative to the Prx1-derived EV subpopulations. To characterize the effects of these small EVs on a bone cell target, cultured mouse bone marrow stromal cells were treated with Prx1 or Ocn EVs, and mRNA-sequencing was performed. Pathways involved in ossification, bone development, and extracellular matrix interactions were regulated by both EV subpopulations, whereas a few pathways including advanced glycation end-products signaling were uniquely regulated in the Ocn EV subpopulation, underlying important biological effects of specific EV subpopulations within the bone marrow microenvironment. These data demonstrate that EV isolation in vivo using the CAGS-Snorkel mouse model is a useful tool in characterizing the cargo and understanding the biology of tissue-specific EVs. Moreover, while bone mesenchymal cell populations share a common EV secretory profile, we uncover key differences based on the stage of osteoblastic differentiation that may have important biological consequences.
Stereotactic Radiosurgery With Versus Without Neoadjuvant Endovascular Embolization for Brain Arteriovenous Malformations With Associated Intracranial Aneurysms
Becerril‐Gaitan, Andrea , Nguyen, Justin H. , Lee, Cheng‐Chia , Ding, Dale , Woo, Shiao Y. , Warnick, Ronald E. , Feliciano, Caleb , Rodriguez-Mercado, R, Cockroft, Kevin M. , Simon, Scott D. , Lee, John, Sheehan, Jason P. , Chen, Ching-Jen , Ding, Dale , Nguyen, Justin, Cifarelli, Christopher P. , Liščák, Roman , Williams, Brian J. , Yusuf, Mehran Behruj , Trifiletti, Daniel M. , Mathieu, David , Kondziolka, Douglas , Lee, John, Chen, Ching‐Jen

Mayo Clinic

Neurosurgery | August 22, 2024 | Volume: 96 | Issue: 4 | Pages: 787-793

10.1227/neu.0000000000003152 | PMID 39171929 Get It

BACKGROUND AND OBJECTIVES: Stereotactic radiosurgery (SRS) with neoadjuvant embolization is a treatment strategy for brain arteriovenous malformations (AVMs), especially for those with large nidal volume or concomitant aneurysms. The aim of this study was to assess the effects of pre-SRS embolization in AVMs with an associated intracranial aneurysm (IA). METHODS: The International Radiosurgery Research Foundation AVM database from 1987 to 2018 was retrospectively reviewed. SRS-treated AVMs with IAs were included. Patients were categorized into those treated with upfront embolization (E + SRS) vs stand-alone SRS (SRS). Primary end point was a favorable outcome (AVM obliteration + no permanent radiation-induced changes or post-SRS hemorrhage). Secondary outcomes included AVM obliteration, mortality, follow-up modified Rankin Scale, post-SRS hemorrhage, and radiation-induced changes. RESULTS: Forty four AVM patients with associated IAs were included, of which 23 (52.3%) underwent pre-SRS embolization and 21 (47.7%) SRS only. Significant differences between the E + SRS vs SRS groups were found for AVM maximum diameter (1.5 ± 0.5 vs 1.1 ± 0.4 cm 3 , P = .019) and SRS treatment volume (9.3 ± 8.3 vs 4.3 ± 3.3 cm 3 , P = .025). A favorable outcome was achieved in 45.4% of patients in the E + SRS group and 38.1% in the SRS group ( P = .625). Obliteration rates were comparable (56.5% for E + SRS vs 47.6% for SRS, P = .555), whereas a higher mortality rate was found in the SRS group (19.1% vs 0%, P = .048). After adjusting for AVM maximum diameter, SRS treatment volume, and maximum radiation dose, the likelihood of achieving favorable outcome and AVM obliteration did not differ between groups ( P = .475 and P = .820, respectively). CONCLUSION: The likelihood of a favorable outcome and AVM obliteration after SRS with neoadjuvant embolization in AVMs with concomitant IA seems to be comparable with stand-alone SRS, even after adjusting for AVM volume and SRS maximum dose. However, the increased mortality among the stand-alone SRS group and relatively low risk of embolization-related complications suggest that these patients may benefit from a combined treatment approach.
Fecal Microbiota Transplantation (FMT) and Clinical Outcomes among Inflammatory Bowel Disease (IBD) Patients: An Umbrella Review
Malik, Sheza , Arsalan, Syed Shakeeb , Shadali, Abul Hasan, Khan, Hajra, Christof, Michael , Niu, Chengu , Adler, Douglas G., Naqvi, Syed Arsalan Ahmed , Khan, Hajra, Schwartz, David A.

Mayo Clinic

No container title available | August 22, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-4758866/v1 Get It

Abstract Background and Aims: Recent systematic reviews and meta-analyses (SRMAs) have shown inconsistent effectiveness of FMT among IBD patients. This study aimed to appraise the evidence for clinically relevant outcomes with FMT in IBD patients using published SRMAs. Methods: We searched major databases from inception through Nov 2023 to identify SRMAs assessing the effectiveness of FMT in IBD patients. Primary outcomes included clinical remission, clinical response, endoscopic remission/response, a composite endpoint, and adverse effects. We included SRMAs investigating FMT's effect in IBD patients using RCTs and observational studies data. Methodological quality and evidence certainty were assessed using AMSTAR 2 and GRADE. Results: Out of 106 citations, 16 SRMAs were included with varying study sizes (2 to 60 primary studies) and participants (112 to 1169 per SRMA). Five SRMAs assessed FMT in IBD, while 11 focused on Ulcerative Colitis (UC). Seven SRMAs included RCTs only, and nine included both RCTs and observational studies. Methodological quality was critically low in 9 SRMAs (56%) and low in 7 studies (44%). FMT showed clinical remission benefit in all 16 SRMAs, with varying certainty: 3 high, 4 moderate, 4 low, and 5 very low. Endoscopic remission/response was reported in 5 meta-analyses on UC, with 1 high, 3 moderate, and 1 very low certainty. Combined clinical remission and endoscopic response were reported in 3 SRMAs on UC, with 1 low and 2 moderate certainty. Adverse events were reported in 6 SRMAs, with 1 high, 3 moderate, 1 low, and 1 very low certainty. Conclusion: Current evidence shows potential benefits of FMT in IBD, particularly UC, supported by significant associations in 16 meta-analyses. However, poor methodological quality and variability in evidence certainty call for high-quality RCTs to strengthen the evidence.